Celexor Bio is the tenth company formed by Aditum Bio

Celexor Bio是Aditum Bio成立的第十家公司

OAKLAND, Calif. , Sept. 21, 2023 /PRNewswire/ -- Aditum Bio, the biotech investment firm cofounded in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research (NIBR) Dr. Mark Fishman, today announced the formation of Celexor Bio, a portfolio company created for the development of novel therapies for inflammatory disorders.

加利福尼亚州奥克兰市，2023年9月21日/PRNewswire/-生物技术投资公司Aditum Bio由前诺华首席执行官Joe Jimenez和诺华生物医学研究所（NIBR）前总裁Mark Fishman共同创立，今天宣布成立Celexor Bio，这是一家为开发炎症性疾病新疗法而创建的投资组合公司。

Celexor Bio is being formed in connection with the in-licensing of a depleting antibody targeting immunoglobulin-like transcript 7 (ILT7), a highly specific cell surface marker found on plasmacytoid dendritic cells (pDCs), which is anticipated to close later this month. The compound (IMG-018) is being licensed from Inmagene Biopharmaceuticals and will be renamed CLXR-901..

Celexor-Bio正在与针对免疫球蛋白样转录物7（ILT7）的消耗性抗体的许可形成，ILT7是浆细胞样树突状细胞（pDC）上发现的高度特异性的细胞表面标记，预计将在本月晚些时候关闭。该化合物（IMG-018）获Inmagene Biopharmaceuticals许可，将更名为CLXR-901。。

pDCs are a dendritic cell subtype specialized in secreting high levels of Type I interferons and other pro-inflammatory cytokines. The pathological activation of pDCs has been implicated in the pathophysiology of several autoimmune and inflammatory diseases. CLXR-901 rapidly and potently depletes these pathological cells, offering a potentially safe and effective alternative for severe autoimmune and inflammatory disorders..

pDC是专门分泌高水平I型干扰素和其他促炎细胞因子的树突细胞亚型。pDC的病理活化涉及几种自身免疫和炎性疾病的病理生理学。CLXR-901快速有效地消耗这些病理细胞，为严重的自身免疫性和炎性疾病提供了一种潜在安全有效的替代方案。。

'Aditum Bio's unique incubator model enables us to accelerate the development of novel medicines, and we look forward to bringing this promising therapy to patients in need' said Joe Jimenez, Co-Founder and Managing Director of Aditum Bio. Dr. Mark Fishman, Co-Founder and Chair of the Medical and Scientific Advisory Boards, added, 'pDCs play a key role in the pathophysiology of multiple autoimmune and inflammatory diseases.

“Aditum Bio独特的孵化器模式使我们能够加速新药的开发，我们期待着为有需要的患者带来这种有希望的治疗方法，”Aditum Bio的联合创始人兼总经理Joe Jimenez博士说。医学和科学咨询委员会联合创始人兼主席Mark Fishman博士补充说，pDC在多种自身免疫性和炎性疾病的病理生理学中起关键作用。

By directly depleting the pathological cells, CLXR-901 may offer a safe and effective alternative for these challenging disorders.'.

通过直接消耗病理细胞，CLXR-901可能为这些具有挑战性的疾病提供安全有效的替代方案。

Celexor Bio is the tenth company launched by Aditum Bio, whose mission is to give large patient populations access to medicines which otherwise may not be developed. To speed these drugs to market, Aditum Bio fosters an incubator model, focusing on the translational phase of drug development. The 'spin out' model enables a nimble, start-up culture with a dedicated team of managers supported by Aditum's in-house team of operational and technical area experts, ranging from nonclinical pharmacology and CMC to regulatory affairs and clinical operations. .

Celexor Bio是Aditum Bio推出的第十家公司，其使命是让大量患者获得可能无法开发的药物。为了加速这些药物的上市，Aditum Bio培育了一个孵化器模型，专注于药物开发的转化阶段。“衍生”模式使Aditum内部运营和技术领域专家团队（从非临床药理学和CMC到法规事务和临床运营）支持的专业管理团队成为灵活的初创文化。 .

About Aditum Bio

关于Aditum Bio

Aditum Bio is committed to improving public health by accelerating R&D in disease areas with both large and more targeted patient populations, where medical innovation can have a significant impact. Aditum Bio focuses on mechanisms of disease, in-licenses promising drug candidates directed at such pathophysiology, and spins out individual companies dedicated to bringing each candidate through clinical trials.

Aditum Bio致力于通过加速疾病领域的研发来改善公共卫生，这些疾病领域的患者人数众多且更有针对性，医疗创新可以产生重大影响。Aditum Bio专注于疾病机制，许可有希望的候选药物针对这种病理生理学，并推出致力于通过临床试验为每个候选人带来的个别公司。

For more information, please visit www.aditumbio.com..

欲了解更多信息，请访问www.aditumbio.com。。

About Inmagene Biopharmaceuticals

关于Inmagene生物制药

Inmagene is a global clinical-stage biotech company focused on developing novel therapeutics for immunological and inflammatory diseases. It has four clinical assets and an innovative preclinical pipeline. The company is developing its highly differentiated clinical assets, including IMG-007 (anti-OX40 mAb with extended half-life and silenced ADCC function), IMG-004 (BTKi with long half-life and pharmacodynamic duration) and IMG-008 (long-acting anti-IL-36R mAb).

Inmagene是一家全球临床阶段生物技术公司，专注于开发免疫和炎症疾病的新疗法。它有四个临床资产和一个创新的临床前管道。该公司正在开发其高度分化的临床资产，包括IMG-007（具有延长的半衰期和沉默的ADCC功能的抗OX40 mAb），IMG-004（具有长半衰期和药效学持续时间的BTKi）和IMG-008（长效抗IL-36R mAb）。

With its partners, Inmagene is co-developing IMG-020 (izokibep, an anti-IL-17 fusion protein), in which Inmagene owns certain global upside in addition to development and commercialization rights in some Asia regions. Further information is available at www.inmagenebio.com..

与其合作伙伴，Inmagene正在共同开发IMG-020（izokibep，一种抗IL-17融合蛋白），其中Inmagene除了在亚洲一些地区的开发和商业化权利外，还拥有一定的全球优势。更多信息请访问www.inmagenebio.com。。

SOURCE Aditum Bio

来源Aditum Bio